about
Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyClinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?PET imaging of bacterial infections with fluorine-18-labeled maltohexaose.Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections.SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patientsStrategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesDoes Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachA 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Antimicrobial stewardship of β-lactams in intensive care units.A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients.High-risk prescribing in an Irish primary care population: Trends and variation.The use and risks of antibiotics in critically ill patients.Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects.Junior doctors' preparedness to prescribe, monitor, and treat patients with the antibiotic vancomycin in an Australian teaching hospital.What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapyAn international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.Collaborative Pharmacokinetic-Pharmacodynamic Research for Optimization of Antimicrobial TherapyThe role of antibiotic stewardship in limiting antibacterial resistance among hematology patients.Peaks and troughs: variations in the availability of therapeutic drug monitoring in critical care units across London.Delivering precision antimicrobial therapy through closed-loop control systems.Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients.[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
P2860
Q28551453-77174064-3B50-4582-A26C-57D43915D2B8Q33784516-E4184CDB-B800-45D8-8A67-5F5CD533BB19Q33798203-3397D1DF-966F-456F-A9CF-7ABEA45CA1BEQ33821554-E1B75B0C-449A-423D-B6D3-DABFACCA3251Q34274190-51B81389-1B00-43FA-A220-10952C4FF0D1Q34329290-9756A06A-933A-4CED-B46C-16B42917F55AQ34894900-88911422-E025-47D7-887F-5666C3643658Q35602940-00354AE1-60D0-489A-9DA3-4491C1EDD53BQ35694058-5F93A853-0F8A-4853-AD01-251B51982EBCQ35942407-746D2E95-100C-4639-AB42-336D26ABC026Q35986250-5F96EDAB-6EE2-48EC-A6E6-2087574802F2Q36287127-00F730D1-0323-4340-9788-DB78B45807F5Q36396195-5A21A992-DEBC-4460-A93B-14146B3E7CFFQ36802059-AE874F34-5D7F-4EAD-8BD6-73A218F527BFQ37203803-ED3E69DC-A926-4A60-B1B9-BB07567E80B9Q38004063-4F4A6E36-C664-482A-AD9A-9C0B63356255Q38138835-AE2E432B-C6B5-485C-8037-5EBF640EA6A3Q38198157-95D25487-5B68-4812-B6F9-EE3DFD764B6BQ38271273-06F60D63-BFE7-4C41-ADBD-CFD81AC7D601Q38682225-1560B6D5-808E-40C9-9F17-3D38A00BE167Q38767901-4D9A3361-6097-40E6-8C4F-0135867A3D27Q38850670-745D1E5B-7EC8-4756-A5D2-34299EF0C66BQ38865905-2622F4B3-C61E-411E-A7AB-FA8ED160AE0EQ38884589-93D77754-473B-45D9-9C74-43389EE4DCC3Q40138068-342FB8DC-8F6A-4A6A-AC6C-DAD66E7F669DQ40172540-9735302D-5411-4AFB-8A48-96178415BFB8Q40541397-8D753D26-575C-4910-B81B-C0AFB1EB42AFQ41435865-5258689A-51C8-4676-81FA-5A9F2A4F0319Q42232248-992F07C2-2C68-4CF1-9F64-3C1786F1AEFCQ42236097-EE050AF3-2941-4B5E-8484-960EF61A5A36Q42388163-6BA3A7B1-CC5E-45C0-BDAF-5F17E19A3446Q42831481-6F9A68EA-13C3-469E-9441-09F5DBAE3522Q45909591-8339A495-2A04-4B82-9A74-18126B258EE5Q47276911-94764CE8-B3DC-49D7-A510-A8FB504BC88AQ47677698-9E29D804-757C-401F-9305-C88EADCE0E98Q47939381-3272E96C-0A62-4CF7-B9CE-E2AEA0F2FCFFQ48154458-E8129538-7343-46F2-8969-D6F52625FEE0Q49589601-E149A428-8B6B-4561-815F-ADBBF29FADA4Q50079038-3F634D35-69C6-4EA0-8B54-E1FE271ECDA7Q50719557-6E276815-0588-4F18-94E0-4012439FE3D4
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Therapeutic drug monitoring of antimicrobials.
@ast
Therapeutic drug monitoring of antimicrobials.
@en
type
label
Therapeutic drug monitoring of antimicrobials.
@ast
Therapeutic drug monitoring of antimicrobials.
@en
prefLabel
Therapeutic drug monitoring of antimicrobials.
@ast
Therapeutic drug monitoring of antimicrobials.
@en
P2860
P50
P1476
Therapeutic drug monitoring of antimicrobials.
@en
P2093
Ross Norris
P2860
P356
10.1111/J.1365-2125.2011.04080.X
P407
P577
2012-01-01T00:00:00Z